• Spanish Registry of Esophagogastric Cancer

  NCT04958720

  RecruitingObservationalUpdated Jul 3, 2025
• Cancer-related Venous Thromboembolic Disease - Cohort Study

  NCT06393764

  RecruitingObservationalUpdated Jun 15, 2026
• GETNE Registration of Thyroid Cancer

  NCT03765333

  RecruitingObservationalUpdated Oct 3, 2024
• Thoracic Tumours Register

  NCT02941458

  RecruitingObservationalUpdated Apr 23, 2026
• THrombo-Embolic Event in Onco-hematology

  NCT03826043

  CompletedInterventionalNot ApplicableUpdated Sep 30, 2025
• Institutional Registry of Thromboembolic Disease

  NCT01372514

  Unknown statusObservationalUpdated Aug 13, 2019

ClinicalTrials.gov ID

NCT03855592

Lead Sponsor

Fundación Sociedad Española de Oncologia MédicaOTHER

Overall Status

Recruiting

Study Type

Observational

Enrollment

700Estimated

Last Update Posted

May 16, 2025Actual

Start Date

Jul 4, 2018Actual

Primary Completion Date

Jul 2026Estimated

Completion Date

Jul 2026Estimated

Official Title

Observational Epidemiological Study of Cancer-associated Thrombosis: Registry of Thrombosis & NEoplasia of SEOM (TESEO Study)

Brief Summary

Epidemiological, observational, non-interventional, multicentric study on patients diagnosed with cancer who develop a venous or arterial thromboembolic episode, symptomatic or incidental, within a month prior to cancer diagnosis or at anytime after such diagnosis

• Thromboembolism
• Cancer

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Over 18 years of age with a histologically confirmed diagnosis of malignant tumor.
• Venous or arterial thromboembolism episode, symptomatic or incidental, in the month prior or any time after the cancer diagnosis and in the three previous months to enrollment, confirmed with an imaging technique: Doppler echocardiography, computed tomography (CT) angiography, etc.
• Signing of informed consent.

Exclusion Criteria:

• Clinical diagnosis of thromboembolic event without radiological confirmation.
• Presenting a single episode of superficial thrombophlebitis without association with another thromboembolic event.
• Each patient will be recorded just once, and therefore a second thromboembolic event will be considered a rethrombosis and will be recorded as such. Patients with a rethrombosis and a previous thromboembolic event before the start of the study in each center will not be able to be included.

Observational Model

Other

Time Perspective

Prospective

Lead Sponsor

Fundación Sociedad Española de Oncologia MédicaOTHER

investigacion@mfar.net